Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera

Blood

Volumn 95, Issue 8, 2000, Pages 2569-2576

  Temerinac, Snežana ^b   Klippel, Steffen ^b   Strunck, Elisabeth ^b   Röder, Sabine ^b   Lübbert, Michael ^b   Lange, Winand ^b   Azemar, Marc ^b   Meinhardt, Gerold ^b   Schaefer, Hans Eckart ^b   Pahl, Heike L ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CELL RECEPTOR; COMPLEMENTARY DNA; CYTARABINE; GENE PRODUCT; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; ERYTHROCYTOSIS; FEMALE; FETUS LIVER; GENE EXPRESSION; GENE ISOLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR CLONING; MYELOPROLIFERATIVE DISORDER; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN STRUCTURE; THROMBOCYTHEMIA; TISSUE SPECIFICITY;

EID: 0034656066     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.8.2569.008k08_2569_2576     Document Type: Article

References (45)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372.
2. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann BA. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295:913.
3. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189.
4. Fialkow PJ, Jacobson JR, Singer JW, Sacher RA, W. MR, Neefe JR. Philadelphia chromosome (Ph1)-negative chronic myelogenous leukemia (CML): a clonal disease with origin in a multipotent stem cell. Blood. 1980;56:70.
5. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58:916.
6. Bilgrami S, Greenberg BR. Polycythemia rubra vera. Semin Oncol. 1995;22:307.
7. Kreipe H, Radzun HJ, Bartels H, v. Heyden H-W, Löffler H, Parwaresch MR. Detection of clonality and stem cell mutations in chronic myelopoliferative disorders. Verh Dtsch Ges Pathol. 1990; 74:49.
8. Kreipe H, Feigner J, Jaquet K, Heidorn K, Radzun HJ, Parwaresch R. DNA analysis to aid in the diagnosis of chronic myeloproliferativa disorders. Am J Clin Pathol. 1992;98:46.
9. Tsukamoto N, Morita K, Maehara T, et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement [see comments]. Br J Haematol. 1994;86:253.
10. Dai C-H, Krantz SB, Means RT, Hom ST, Gilbert HS. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J Clin Invest. 1991;87:391.
11. Dai CH, Krantz SB, Dessypris EN. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin 3 and granulocyte-macrophage colony-stimulating factor. Blood. 1992;80:891.
12. Dai CH, Krantz SB, Green WF, et al. Polycythemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol. 1994;86:12.
13. Martin JM, Gandhi K, Jackson WR, Dessypris EN. Hypersensitivity of polycythemia vera megakaryocytic progenitors to thrombopoetin. Blood. 1996;88:94a.
14. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood. 1994;83:99.
15. Mirza AM, Ezzat S, Axelrad AA. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Blood. 1997;89: 1862.
16. Moliterno AR, Hankins D, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med. 1998;338:572.
17. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338:564.
18. Muta K, Krantz SB. Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor 1 as well as erythropoietin. J Cell Physiol. 1993;156:264.
19. Lui Q, Schacher D, Hurth C, Freund GG, Dantzer R, Kelley KW. Activation of phosphatidylinositol 3′-kinase by insulin-like growth factor 1 rescues promyeloid cells from apoptosis and permits their differentiation into granulocytes. J Immunol. 1997;159:829.
20. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in Polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23:132.
21. Kruisbeck AM, Margulies DH, Shevach EM, Strober W. Current Protocols in Immunology. New York: John Wiley & Sons; 1991.
22. Pahl HL, Krauss B, Schulze-Osthoff K, et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-KB. J Exp Med. 1996;183:1829.
23. Al Safadi L, Kohler G, Schaefer HE. Classification of acute myeloid leukaemia in trephine biopsies with special reference to lactoferrin. Anticancer Res. 1998;18:3677.
24. Mufti GJ, Flandrin G, Schaefer HE, Sandberg AA, Kanfer EJ. An Atlas of Malignant Haematology: Cytology, Histology and Cytogenetics. London: Martin Dunitz; 1996.
25. Schaefer HE. How to fix, decalcify and stain paraffin embedded bone marrow biopsies. In: Lennert K, Hübner, K, eds. Pathology of the Bone Marrow. Stuttgart: Gustav Fischer-Verlag; 1994:6.
26. Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator, comparison to other members of the Ly-6 family and snake venom α-neurotoxins. FEBS Lett. 1994;349:163.
27. Kieffer B, Driscoll PC, Campbell ID, Willis AC, van der Merwe PA, Davis SJ. Three-dimensional solution structure of the extracellular region of the complement regulatory protain CD59, a new cell-surface protein domain related to snake venom neurotoxins. Biochemistry. 1994;33:4471.
28. Ploug M, Kjalke M, Ronne E, Weidle U, Hoyer-Hansen G, Dano K. Localization of the disuffide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. J Biol Chem. 1993;268:17,539.
29. Ploug M, Behrendt N, Lober D, Dano K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Hemost. 1991;17:183.
30. MacNeil I, Kennedy J, Godfrey DI, et al. Isolation of a cDNA encoding thymic shared antigen-1. J Immunol. 1993;151:6913.
31. Sugita Y, Nakano Y, Oda E, et al. Determination of carboxy-terminal residue and disulfide bonds of MACIF (CD59), a glycosyl-phosphatidylinositol-anchored membrane protein. J Biochem. 1993;114:473.
32. Wang Y, Dang J, Johnson LK, Selhamer JJ, Doe WF. Structure of the human urokinase receptor gene and its similarity to CD59 and the Ly-6 family. Eur J Biochem. 1995;227:116.
33. Casey JR, Petranka JG, Kottra J, Fleenor DE, Rosse WF. The structure of the urokinase-type plasminogen activator receptor gene. Blood. 1994;84:1151.
34. Petranka JG, Fleenor DE, Sykes K, Kaufmann RE, Rosse WF. Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. Proc Natl Acad Sci U S A. 1992;89:7876.
35. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990;71:1.
36. Ninomiya H, Sims PJ. The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the "b" domain of C9. J Biol Chem. 1992;267:13,675.
37. Noel LS, Champion BR, Holley CL, et al. RoBo-1, a novel member of the urokinase plasminogen activator receptor/CD59/Ly6/Snake toxin family selectively expressed in rat bone and growth plate cartilage. J Biol Chem. 1998;273:3878.
38. Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H. GPI-anchored cell surface molecules complexed to protein tyrosine kinases. Science. 1991;254:1016.
39. Konakova M, Hucho F, Schleuning W-D. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem. 1998;253:421.
40. Dumler I, Weis A, Mayboroda OA, et al. The Jak/ Stat pathway and urokinase receptor signalling in human aortic vascular smooth muscle cells. J Biol Chem. 1998;273:315.
41. Bohuslav J, Horejsi V, Hansmann C, et al. Urokinase plasminogen activator receptor p2-integrins, and src-kinases within a single receptor complex of human monocytes. J Exp Med. 1995;181: 1381.
42. Koshelnick Y, Ehart M, Hufnagl P, Heinrich PC, Binder BR. Urokinase receptor is associated with the components of the JAK/STAT1 signalling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J Biol Chem. 1997;272:28,563.
43. Behrendt N, Plough M, Patthy L, Houen G, Blasi F, Dano K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem. 1991;266:7842.
44. Appella E, Robinson EA, Ulrich SJ, et al. The receptor-binding sequence of urokinase: a biological function for the growth-factor module of proteases. J Biol Chem. 1987;262:4437.
45. Shih L-Y, Lee C-T. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood. 1994;83:744.